MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes

Table 3 Clinical and laboratory aspects of the second confirmation analysis recruited patients

Parameter	Healthy, n = 225	T2DM, n = 200	LC, n = 270	HCC, n = 200	P value
Age in yr	49.92 ± 7.14	53.68 ± 9.48	57.18 ± 7.30	56.23 ± 8.14	0.26
ALP in IU/L	64.2 ± 20.8	134.3 ± 36.9	103.18 ± 37.5	134.6 ± 83.5	< 0.0001
ALT in IU/L	30.2 ± 15.6	58 ± 18	31.8 ± 21.08	206.8 ± 133.31	0.001
AST in IU/L	28.6 ± 10.3	52.1 ± 18.0	58.18 ± 41.6	447.07 ± 249.90	< 0.0001
Bilirubin, total in mg/dL	0.6 ± 0.2	0.39 ± 0.19	4.64 ± 7.90	8.39 ± 8.83	< 0.0009
Bilirubin, direct in mg/dL	0.2 ± 0.1	0.86 ± 0.28	2.98 ± 6.5	6.36 ± 7.8	< 0.0001
Albumin in g/dL	4.3 ± 1.2	4.01 ± 0.57	2.53 ± 0.49	2.33 ± 0.39	< 0.0001
Hemoglobin in g/dL	11.9 ± 2.1	11.81 ± 4.2	9.20 ± 2.41	10.15 ± 1.98	< 0.0001
AFP in ng/mL	9.33 ± 1.82	3.72 ± 1.15	35.56 ± 41.23	267.8 ± 221.9	< 0.0001
Platelet count as × 103/µL	240 ± 97.6	320 ± 68.2	147.9 ± 129.6	97.8 ± 53.6	< 0.0001
leukocyte count as × 103/µL	6.8 ± 2.4	8.6 ± 2.42	6.17 ± 4.1	7.18 ± 3.18	< 0.0001
INR	1.25 ± 0.23	1.43 ± 0.51	1.81 ± 0.52	1.95 ± 0.63	< 0.0001
Creatinine in mg/dL	0.7 ± 0.2	0.98 ± 0.31	0.99 ± 0.25	1.41 ± 0.78	< 0.0001
GGT in U/L	12.0 ± 3.0	33.0 ± 12.8	41.54 ± 25.6	51.38 ± 32.86	< 0.0001
BUN in mg/dL	29.2 ± 3.4	70.0 ± 20.3	39.9 ± 28.6	71.54 ± 52.83	< 0.0001

Data are presented as mean ± standard deviation. Clinical data was analyzed by analysis of variance analysis. A result was considered to be statistically significant if P < 0.05. AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; HCC: Hepatocellular carcinoma; INR: International normalized ratio; LC: Liver cirrhosis; T2DM: Type 2 diabetes patients.